Is there life after technetium: what is the potential for developing new broad-based radionuclides?

No abstract is available for this paper.

• Publication year

  1996

• Venue

  Seminars in nuclear medicine

• Publication date

  1996-04-01

• Fields of study

  Medicine, Physics

• Identifiers
  DOI 10.1016/S0001-2998(96)80033-XPMID 8723506
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Criteria for the Selection of Radionuclides for Targeting Nuclear Antigens for Cancer Radioimmunotherapy

  1996cited by this paper
• Development and evaluation of copper-67 and samarium-153 labeled conjugates for tumor radioimmunotherapy

  1995cited by this paper
• Anti-chelate antibodies after intraperitoneal yttrium-90-labeled monoclonal antibody immunoconjugates for ovarian cancer therapy.

  1995cited by this paper
• Tin-117m(4+)-DTPA for palliation of pain from osseous metastases: a pilot study.

  1995cited by this paper
• Isotopes for medicine and the life sciences

  1995cited by this paper
• Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides.

  1995cited by this paper
• Evaluation of chelating agents for radioimmunotherapy with scandium-47

  1995cited by this paper
• Current status of radioimmunotherapy.

  1994cited by this paper
• Development and evaluation of copper-67 labeled DOTA and TETA immunoconjugates for radioimmunotherapy

  1994cited by this paper
• Production and supply of radioisotopes with high-energy particle accelerators current status and future directions

  1994cited by this paper
• Biodistribution of Sn-117m(4+)DTPA for palliative therapy of painful osseous metastases.

  1993cited by this paper
• Energy Department proposes two isotope initiatives.

  1993cited by this paper
• Selection of radionuclides for radioimmunotherapy.

  1993cited by this paper
• Early closing of accelerator could impede nuclear medicine research.

  1993cited by this paper
• PET scanning of iodine-124-3F9 as an approach to tumor dosimetry during treatment planning for radioimmunotherapy in a child with neuroblastoma.

  1992cited by this paper
• Production and Evaluation of Sc-47 for Radioimmunotherapy

  1992cited by this paper
• Phosphorus-32 radiopharmaceuticals for the treatment of painful osseous metastases.

  1992cited by this paper
• The use of a new radiopharmaceutical, 97Ru-DISIDA, and of 99Tcm-sulphur colloid for the simultaneous evaluation of duodenogastric reflux and gastric emptying.

  1992cited by this paper
• Therapeutic radionuclides: production and decay property considerations.

  1991cited by this paper
• Progress in research on ligands, nuclides and techniques for labeling monoclonal antibodies.

  1991cited by this paper
• Optimal antibody-radionuclide combinations for clinical radioimmunotherapy: a predictive model based on mouse pharmacokinetics.

  1991cited by this paper
• Radiolabelled monoclonal antibodies in oncology. III. Radioimmunotherapy.

  1991cited by this paper
• National Biomedical Tracer Facility planning and feasibility study

  1991cited by this paper
• Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: results of a double-blind crossover comparison with placebo.

  1991cited by this paper
• A new separation procedure for 67Cu from proton irradiated Zn

  1991cited by this paper
• Technetium and rhenium in chemistry and nuclear medicine

  1990cited by this paper
• Development of a new radiolabel (203Pb) and new chelating agents for labeling monoclonal antibodies for imaging.

  1990cited by this paper
• Energy agency examines radioisotope needs in preparation for the future.

  1990cited by this paper
• Improved in vivo stability and tumor targeting of bismuth-labeled antibody.

  1990cited by this paper
• The design and operation of the upgraded BLIP facility for radionuclide research and production

  1990cited by this paper
• A new cholescintigraphic agent: ruthenium-97-DISIDA.

  1989cited by this paper
• Production of high specific activity 117mSn with the szilard‐chalmers process

  1989cited by this paper
• Labeling monoclonal antibodies and F(ab')2 fragments with the alpha-particle-emitting nuclide astatine-211: preservation of immunoreactivity and in vivo localizing capacity.

  1989cited by this paper
• Copper-67-labeled monoclonal antibody Lym-1, a potential radiopharmaceutical for cancer therapy: labeling and biodistribution in RAJI tumored mice.

  1988cited by this paper
• An improved generator for the production of 212Pb and 212Bi from 224Ra.

  1988cited by this paper
• Direct dose confirmation of quantitative autoradiography with micro-TLD measurements for radioimmunotherapy.

  1988cited by this paper
• Radiolabeled Monoclonal Antibodies for Imaging and Therapy

  1988cited by this paper
• Patient biodistribution of intraperitoneally administered yttrium-90-labeled antibody.

  1988cited by this paper
• Skeletal localization of samarium-153 chelates: potential therapeutic bone agents.

  1987cited by this paper
• Radiobiologic implications of the microscopic distribution of energy from radionuclides.

  1987cited by this paper
• Dosimetric aspects of radiolabeled antibodies for tumor therapy.

  1986cited by this paper
• Bismuth-212-labeled anti-Tac monoclonal antibody: alpha-particle-emitting radionuclides as modalities for radioimmunotherapy.

  1986cited by this paper
• Correlating Labeling Chemistry and in-vitro Test Results with the Biological Behavior of Radiolabeled Proteins *

  1986cited by this paper
• Production of no-carrier added 67Cu.

  1986cited by this paper
• 90Yttrium antiferritin--a new therapeutic radiolabeled antibody.

  1986cited by this paper
• The development and in-vivo behavior of tin containing radiopharmaceuticals--I. Chemistry, preparation, and biodistribution in small animals.

  1985cited by this paper
• Radiation absorbed dose estimates at the cellular level for some electron-emitting radionuclides for radioimmunotherapy.

  1984cited by this paper
• Radionuclide selection and model absorbed dose calculations for radiolabeled tumor associated antibodies.

  1984cited by this paper
• Preparation of a 211At-IgG conjugate which is stable in vivo.

  1984cited by this paper
• Uptake of ruthenium-labeled transferrin in healing wounds.

  1983cited by this paper
• Lethality of Auger electrons from the decay of bromine-77 in the DNA of mammalian cells.

  1982cited by this paper
• Technetium-99m: an historical perspective.

  1982cited by this paper
• Ruthenium-97 DTPA: a new radiopharmaceutical for cisternography.

  1981cited by this paper
• Ruthenium-97 hepatobiliary agents for delayed studies of the biliary tract. I. ru-97 PIPIDA: concise communication.

  1981cited by this paper
• Frontiers in Nuclear Medicine

  1980cited by this paper
• Ruthenium-97 labeled compounds: a new class of radiopharmaceuticals. [Preparation, tissue distribution, and imaging studies]

  1978cited by this paper
• Biological damage from the Auger effect, possible benefits

  1975cited by this paper
• Copper-67-Labeled Monoclonal Antibody Lym- 1, A Potential Radiopharmaceutical for CancerTherapy:Labelingand Biodistribution in RAJI Tumored Mice

  year unknowncited by this paper

• The preparation, biodistribution, and human’s absorbed dose evaluation of Radio-Scandium-HYNIC-TOC for somatostatin-receptor-positive neuroendocrine tumors therapy by animal study

  2022cites this paper
• Replacement of Pt-based anticancer drugs by Ru-analogues-a mini-review

  2020cites this paper
• Design, synthesis and in vitro bioactivity of mixed ligand Ru(II) complexes bearing the fluoroquinolone antibacterial agents

  2019cites this paper
• Mechanistic Aspects of Ligand Substitution on the Cis-Diaqua-Chloro-Tris(Dimethyl Sulfoxide)Ruthenium(II) Complex by Some Sulfur-Containing Bioactive Ligands in Aqueous Medium

  2018cites this paper
• Development of bone seeker radiopharmaceuticals by Scandium-47 and estimation of human absorbed dose.

  2017cites this paper
• PREPARATION, QUALITY CONTROL AND BIO-EVALUATION OF TECHNETIUM-99m LABELED COMPOUNDS FOR INFECTION AND TUMOR IMAGING

  2015cites this paper
• Production of 186gRe radionuclide by deuterons for theragnostic medicine

  2015cites this paper
• Preparation of 99mTc carbonyl DTPA-bevacizumab and its bioevaluation in a melanoma model

  2014cites this paper
• ⁹⁹mTc carbonyl DTPA-rituximab: preparation and preliminary bioevaluation.

  2014cites this paper
• Pharmaceutical grade sodium [99mTc] pertechnetate from low specific activity 99Mo using an automated 99Mo/99mTc-TCM-autosolex generator

  2014cites this paper
• Electrochemical Separation: Promises, Opportunities, and Challenges To Develop Next-Generation Radionuclide Generators To Meet Clinical Demands

  2014cites this paper
• Implementation of Multi-Curie Production of 99mTc by Conventional Medical Cyclotrons

  2014cites this paper
• Therapeutic Radionuclides: Production, Physical Characteristics, and Applications

  2013cites this paper
• 99Mo/(99m)Tc separation: an assessment of technology options.

  2013cites this paper
• Current Directions in Radiopharmaceutical Research and Development

  2011cites this paper
• The ruthenium(II)–arene compound RAPTA-C induces apoptosis in EAC cells through mitochondrial and p53–JNK pathways

  2008cites this paper
• Effect Of The Cucumis sativus Extract In Labeling OF Blood Elements With Technetium-99m.

  2008cites this paper
• Evaluation of the biological effect of brahmi (Bacopa monnieri Linn) extract on the biodistribution of technetium-99m radiopharmaceuticals

  2008cites this paper
• High-resolution X-ray imaging based on curved Bragg mirrors: first results

  2003cites this paper
• A simple two-step approach for introducing a protected diaminedithiol chelator during solid-phase assembly of peptides.

  2002cites this paper
• Model to evaluate the toxic effect of drugs: vincristine effect in the mass of organs and in the distribution of radiopharmaceuticals in mice.

  2001cites this paper
• Future Prospects for Medical Radionuclide Production in The High Flux Isotope Reactor ( HFIR ) at The Oak Ridge National

  2001cites this paper
• High-resolution x-ray imaging using Rowland-circle Bragg optics

  2001cites this paper
• Recent advances in radionuclide therapy.

  2001cites this paper
• Which are the most used radionuclides in the pet and in the spect techniques in the world

  2001cites this paper
• The effect of vincristine on the biodistribution of technetium-99m DTPA, GHA, and DMSA in Balb/c female mice.

  2000cites this paper
• Ultra-high-resolution imaging of small animals: Implications for preclinical and research studies

  1999cites this paper
• Therapeutic radionuclides: Making the right choice

  1996cites this paper